BI 655088 / Boehringer Ingelheim, Sanofi - LARVOL DELTA

Anti Human CX3CR1 VHH Molecule Attenuates Venous Neointimal Hyperplasia of Arteriovenous Fistula in Mouse Model. (PubMed, J Am Soc Nephrol) - "CX3CR1 blockade reduces VNH/VS formation by decreasing proinflammatory cues."

Journal • Preclinical • CD68 • CX3CL1 • FN1 • IL1B • TNFA

VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. (PubMed, MAbs) - "BI 655088 is a potent CX3CR1 antagonist that, upon therapeutic dosing, significantly inhibits plaque progression in the standard mouse model of atherosclerosis. BI 655088 represents a novel and highly selective biotherapeutic that could reduce inflammation in the atherosclerotic plaque when added to standard of care treatment including statins, which could result in a significant decrease in atherothrombotic events in patients with existing cardiovascular disease."

Journal